Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | QPCT | Q16769 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6954114 | 0.84 | PKM (0.42) | ALDH1A1LMNAKDM4EKMT2AMEN1 | |
| SCHEMBL6953559 | 0.84 | MAPT (0.49) | KDM4EKMT2AMEN1POLB | |
| SCHEMBL6949344 | 0.83 | ALDH1A1 (0.52) | ALDH1A1LMNAKDM4EKMT2AMEN1 | |
| SCHEMBL6948575 | 0.83 | MGMT (0.42) | ALDH1A1KDM4EKMT2AMEN1POLB | |
| SCHEMBL6949472 | 0.83 | MGMT (0.42) | ALDH1A1KDM4EKMT2AMEN1POLB | |
| SCHEMBL6949517 | 0.83 | MGMT (0.41) | KMT2AMEN1POLBCYP19A1 | |
| SCHEMBL6951003 | 0.82 | MGMT (0.42) | ALDH1A1KDM4EKMT2AMEN1POLB | |
| SCHEMBL6945292 | 0.82 | MGMT (0.45) | KDM4EKMT2AMEN1POLB | |
| SCHEMBL6948893 | 0.81 | PKM (0.41) | ALDH1A1LMNAKDM4EKMT2AMEN1 | |
| SCHEMBL6955505 | 0.81 | MGMT (0.47) | KMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1074549-B1 | Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors | HOFFMANN LA ROCHE (CH) | 2003-11-19 | — | — | EP | disclosed |
| US-6218385-B1 | FOR THERAPY OR PROPHYLAXIS OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS EPILEPSY, STROKE, CHRONIC AND ACUTE PAIN, PSYCHOSIS, SCHIZOPHRENIA, ALZHEIMER'S DISEASE, COGNITIVE DISORDERS AND MEMORY DEFICITS | HOFFMANN-LA ROCHE INC. | 2001-04-17 | — | — | US | disclosed |
| EP-1074549-A2 | Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors | F. HOFFMANN-LA ROCHE AG (CH) | 2001-02-07 | — | — | EP | disclosed |